Astera Labs, Inc.
ALABAstera Labs, Inc.'s multiple sits at its floor because earnings outran a hard multi-year rally — compression born of growth, not neglect. The quarters are still improving, and the P/E sits at the 17th percentile of its own 1-year range.
Biggest watch item: the price is already 23 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (23 weeks in) while the P/E sits at the 17th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +200.0% year on year. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Astera Labs, Inc. trades at $269, in a confirmed uptrend and 23 weeks into that stage. That is +17.1% against its own 200-day average. It sits at 51% of a 52-week range of $112 to $417. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (5 weeks and counting).
Today the stock is in a confirmed uptrend — week 23 of stage 2. At $269 it trades +17.1% versus its 200-day average and sits at 51% of its 52-week range ($112–$417).
Against the market, two honest reads. Cumulative: over the last 2.5 years the stock moved +285% while the S&P 500 moved +45% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (5 weeks and counting; last ahead the week of 2026-08-14) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Astera Labs, Inc. trades at 132.6× P/E, near the bottom of its own range — cheaper only 17% of the time. Its long-run median P/E is 159.2×, measured across 1.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 132.6× is near the bottom of its own range — cheaper only 17% of the time, against a long-run median of 159.2× measured over 1.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Astera Labs, Inc. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 11 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +112.5% | +119.8% | — | — |
| Stock price | +9.8% | — | — | — |
4-Factor Sector Score
51.6/100 — rank 11 of 27 in Semiconductors · 71% evidence confidence
Astera Labs, Inc. scores 51.6 out of 100 against the 27 companies it is compared with in Semiconductors, ranking 11. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 21.8 + 9.9 + 8.8 + 11.1 = 51.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Astera Labs, Inc. reported $0.4 B of revenue in the Jun 26 quarter, +105.3% year on year. That is the 12th straight quarter of year-on-year growth. Over 3 years it has compounded at 119.8% a year. The last full year, FY25, came in at $0.8 B. The last four reported quarters add to $1.2 B.
FY25 revenue came in at $0.8 B (+112.5% on the year), capping 3 years at 119.8% compound. The latest quarter (Jun 26) printed $0.4 B, +105.3% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +100.3% growth against the decade's 119.8% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +100.0% over the last 4 quarters against +123.6%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Astera Labs, Inc.'s operating margin is 23.1% in the Jun 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged −75.0% to 20.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 23.1%, +2.0 pp against the same quarter a year ago. Across 4 fiscal years the operating margin has ranged −75.0%–20.0%.
Why the margin moved: operating margin went +2.0 pp year on year while gross margin went −4.5 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Astera Labs, Inc. earned $0.1 B of net profit in the Jun 26 quarter, +200.0% year on year. It is the 3rd consecutive quarter of growth. Full-year FY25 profit was $0.2 B. That is 38.5% of the quarter's revenue. The same quarter a year earlier earned $0.1 B. 3 of the last 12 reported quarters were loss-making.
Jun 26 profit was $0.1 B, +200.0% year on year — the 3rd consecutive quarter of growth. On the full year, FY25 printed $0.2 B (null).
Why profit moved: revenue contributed +105.3% and the margin +2.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +155.6% vs revenue +100.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Astera Labs, Inc.'s cash-flow history is too thin to judge how much reported profit converts into cash. In FY25 that was $0.3 B of operating cash against $0.2 B of profit. After $0.0 B of capital spending, $0.3 B was left as free cash. Cash resolution here is annual, because quarterly cash statements are not published.
FY25: operating cash of $0.3 B against reported profit of $0.2 B, leaving free cash of $0.3 B after $0.0 B of capital spending.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Astera Labs, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Astera Labs, Inc. earns a ROE of 16% in FY25. That is up from a trough of −38% in FY22. Return on invested capital clears the cost of that capital by +38.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 25.9% net margin on 0.56× asset turns.
FY25 ROE is 16%, recovered from a FY22 trough of −38% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 25.9% net margin × 0.56× asset turns × 1.13× balance-sheet leverage ≈ 16.4% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 63.0% − 25.0% = a +38.0 pp spread. The 25.0% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend
Astera Labs, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Astera Labs, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Debt-to-equity is 0.03 at the latest reading — effectively unlevered; a full borrowings history is not in our numbers.
We hold only the latest reading here: a debt-to-equity of 0.03 — the balance sheet is effectively unlevered, so the returns above are earned, not borrowed. A year-by-year borrowings ladder is not in our numbers for this stock, so we say that rather than draw a chart we cannot support.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
5.8% of Astera Labs, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 2.2 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 5.8% of the float is sold short, and at typical trading volumes it would take about 2.2 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Astera Labs, Inc.: the Z-score reads 93.20. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 93.20 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 93.20.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Micron Technology, Inc.MU | 73.7/100Favorable setup71% evidence | FADING | 29.0/35 Revenue 100% · PAT 100% · OPM change 57.1 pp 83% evidence | 19.2/25 ROCE 51.7% · OPM 80.4% 76% evidence | 11.5/20 P/E 20.6× · PEG — 15% evidence | 14.0/20 RS sector 44.4% · RS bench 59.7% · 1Y 469.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 19.2 + 11.5 + 14 = 73.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Analog Devices, Inc.ADI | 67.9/100Favorable setup85% evidence | ASLEEP | 28.7/35 Revenue 33.6% · PAT 100% · OPM change 10.9 pp 95% evidence | 16.6/25 ROCE 11.6% · OPM 39.5% 76% evidence | 12.2/20 P/E 43.3× · PEG 1.33 65% evidence | 10.4/20 RS sector -14.9% · RS bench 3% · 1Y 47.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 28.7 + 16.6 + 12.2 + 10.4 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Advanced Micro Devices, Inc.AMD | 67.6/100Favorable setup71% evidence | ASLEEP | 27.2/35 Revenue 39.5% · PAT 100% · OPM change 19 pp 83% evidence | 12.9/25 ROCE 9% · OPM 17.3% 76% evidence | 9.3/20 P/E 132.2× · PEG — 15% evidence | 18.2/20 RS sector 28.9% · RS bench 48.2% · 1Y 225.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 12.9 + 9.3 + 18.2 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4NVIDIA CorporationNVDA | 67.3/100Favorable setup85% evidence | TURNING | 20.4/35 Revenue 83.4% · PAT 100% · OPM change 5.4 pp 95% evidence | 21.6/25 ROCE 71.3% · OPM 66.2% 76% evidence | 15.2/20 P/E 26× · PEG 0.77 65% evidence | 10.1/20 RS sector -17.5% · RS bench 2.6% · 1Y 21.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 21.6 + 15.2 + 10.1 = 67.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Broadcom Inc.AVGO | 62.2/100Mixed-positive evidence85% evidence | ASLEEP | 30.0/35 Revenue 48.7% · PAT 100% · OPM change 16.1 pp 95% evidence | 20.4/25 ROCE 26% · OPM 54.3% 76% evidence | 5.9/20 P/E 48.4× · PEG 5.06 65% evidence | 5.9/20 RS sector -29.7% · RS bench -12.5% · 1Y -1.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 30 + 20.4 + 5.9 + 5.9 = 62.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -29.7% and the one-year return is -1.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 6Texas Instruments IncorporatedTXN | 62.0/100Mixed-positive evidence81% evidence | ASLEEP | 20.9/35 Revenue 16.7% · PAT 20% · OPM change 7.6 pp 83% evidence | 20.5/25 ROCE 22.7% · OPM 42.6% 76% evidence | 9.2/20 P/E 45.1× · PEG 2.24 65% evidence | 11.4/20 RS sector -10.4% · RS bench 7.3% · 1Y 45.3%3 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 20.5 + 9.2 + 11.4 = 62 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Silicon Motion Technology CorporationSIMO | 60.8/100Thin evidence · provisional56% evidence | ASLEEP | 22.5/35 Revenue — · PAT — · OPM change 9.4 pp 39% evidence | 14.0/25 ROCE 10.3% · OPM 15.3% 76% evidence | 10.8/20 P/E 39.1× · PEG — 15% evidence | 13.5/20 RS sector 17.5% · RS bench 32.5% · 1Y 161.1%4 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 14 + 10.8 + 13.5 = 60.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Credo Technology Group Holding LtdCRDO | 53.0/100Mixed-positive evidence71% evidence | ASLEEP | 26.5/35 Revenue 100% · PAT 100% · OPM change 15.8 pp 83% evidence | 12.9/25 ROCE 11.1% · OPM 35.7% 76% evidence | 9.9/20 P/E 73.5× · PEG — 15% evidence | 3.7/20 RS sector -25.5% · RS bench -10.5% · 1Y -4.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 26.5 + 12.9 + 9.9 + 3.7 = 53 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -25.5% and the one-year return is -4.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 9Marvell Technology, Inc.MRVL | 52.2/100Mixed-positive evidence67% evidence | FADING | 17.9/35 Revenue 30.6% · PAT — · OPM change 1.8 pp 71% evidence | 9.6/25 ROCE 6.3% · OPM 16.7% 76% evidence | 10.1/20 P/E 62.2× · PEG — 15% evidence | 14.6/20 RS sector 34.3% · RS bench 52% · 1Y 209.3%8 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 9.6 + 10.1 + 14.6 = 52.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10NXP Semiconductors N.V.NXPI | 52.0/100Mixed-positive evidence81% evidence | BASING | 17.9/35 Revenue 8.8% · PAT 38.4% · OPM change 7.1 pp 83% evidence | 12.7/25 ROCE 4.9% · OPM 30.6% 76% evidence | 15.8/20 P/E 23.6× · PEG 0.6 65% evidence | 5.6/20 RS sector -29.5% · RS bench -13.4% · 1Y -2.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 12.7 + 15.8 + 5.6 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Astera Labs, Inc.this pageALAB | 51.6/100Mixed-positive evidence71% evidence | ASLEEP | 21.8/35 Revenue 98.7% · PAT 100% · OPM change 2 pp 83% evidence | 9.9/25 ROCE 6.1% · OPM 22.7% 76% evidence | 8.8/20 P/E 239.1× · PEG — 15% evidence | 11.1/20 RS sector -0.5% · RS bench 16.1% · 1Y 9.8%7 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 9.9 + 8.8 + 11.1 = 51.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12QUALCOMM IncorporatedQCOM | 50.7/100Mixed-positive evidence81% evidence | ASLEEP | 5.8/35 Revenue 1.9% · PAT -20% · OPM change -9 pp 83% evidence | 18.3/25 ROCE 22.6% · OPM 18.5% 76% evidence | 16.4/20 P/E 21.6× · PEG 0.44 65% evidence | 10.2/20 RS sector -17.2% · RS bench 2.5% · 1Y 10.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 5.8 + 18.3 + 16.4 + 10.2 = 50.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 13Microchip Technology IncorporatedMCHP | 49.9/100Mixed-negative evidence74% evidence | ASLEEP | 21.8/35 Revenue 20.9% · PAT — · OPM change 19.7 pp 62% evidence | 9.4/25 ROCE 2.5% · OPM 22.7% 76% evidence | 12.9/20 P/E 136.1× · PEG 0.78 65% evidence | 5.8/20 RS sector -28% · RS bench -12.1% · 1Y 6.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 21.8 + 9.4 + 12.9 + 5.8 = 49.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Tower Semiconductor Ltd.TSEM | 48.9/100Mixed-negative evidence81% evidence | ASLEEP | 20.4/35 Revenue 14.9% · PAT 50.5% · OPM change 8.9 pp 83% evidence | 11.7/25 ROCE 2.9% · OPM 19.6% 76% evidence | 7.6/20 P/E 103× · PEG 2.27 65% evidence | 9.2/20 RS sector -2% · RS bench 13% · 1Y 201.7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 11.7 + 7.6 + 9.2 = 48.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Qorvo, Inc.QRVO | 48.9/100Mixed-negative evidence71% evidence | TURNING | 17.1/35 Revenue -0.2% · PAT 100% · OPM change 8.6 pp 83% evidence | 6.6/25 ROCE 1.9% · OPM 12.3% 76% evidence | 11.3/20 P/E 21.8× · PEG — 15% evidence | 13.9/20 RS sector -4% · RS bench 19.6% · 1Y 24.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 17.1 + 6.6 + 11.3 + 13.9 = 48.9 · Decision use: Price leads the evidence: RS versus the benchmark is 19.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16MACOM Technology Solutions Holdings, Inc.MTSI | 48.9/100Mixed-negative evidence68% evidence | ASLEEP | 22.1/35 Revenue — · PAT — · OPM change 7.8 pp 45% evidence | 15.9/25 ROCE 13% · OPM 23.3% 76% evidence | 5.8/20 P/E 102.1× · PEG 2.95 65% evidence | 5.1/20 RS sector -17.3% · RS bench -2.6% · 1Y 98%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 15.9 + 5.8 + 5.1 = 48.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Intel CorporationINTC | 47.2/100Mixed-negative evidence64% evidence | ASLEEP | 18.8/35 Revenue 7.5% · PAT — · OPM change 16 pp 62% evidence | 6.7/25 ROCE 2.7% · OPM 12.2% 76% evidence | 8.5/20 P/E 837.3× · PEG — 15% evidence | 13.2/20 RS sector 23.1% · RS bench 38.8% · 1Y 241.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 6.7 + 8.5 + 13.2 = 47.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Skyworks Solutions, Inc.SWKS | 46.0/100Thin evidence · provisional56% evidence | TURNING | 13.8/35 Revenue — · PAT — · OPM change -7 pp 39% evidence | 6.8/25 ROCE 0.7% · OPM 4.5% 76% evidence | 10.9/20 P/E 32.4× · PEG — 15% evidence | 14.5/20 RS sector -3.7% · RS bench 20.8% · 1Y 8.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 6.8 + 10.9 + 14.5 = 46 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Lattice Semiconductor CorporationLSCC | 45.4/100Thin evidence · provisional56% evidence | ASLEEP | 20.7/35 Revenue — · PAT — · OPM change 11.5 pp 39% evidence | 9.9/25 ROCE 3.4% · OPM 15.3% 76% evidence | 8.6/20 P/E 678.7× · PEG — 15% evidence | 6.2/20 RS sector -16.8% · RS bench -1.2% · 1Y 47.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 9.9 + 8.6 + 6.2 = 45.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20SiTime CorporationSITM | 44.7/100Thin evidence · provisional51% evidence | ASLEEP | 20.5/35 Revenue 65.2% · PAT — · OPM change 35.7 pp 40% evidence | 5.4/25 ROCE -1.2% · OPM -10.9% 57% evidence | 9.7/20 P/E 98.7× · PEG — 15% evidence | 9.1/20 RS sector -5.2% · RS bench 10.5% · 1Y 75.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 5.4 + 9.7 + 9.1 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Semtech CorporationSMTC | 44.5/100Mixed-negative evidence64% evidence | TURNING | 11.0/35 Revenue 14.3% · PAT — · OPM change -5.4 pp 62% evidence | 5.4/25 ROCE 2.2% · OPM 8.9% 76% evidence | 9.0/20 P/E 218.7× · PEG — 15% evidence | 19.1/20 RS sector 31.3% · RS bench 53.8% · 1Y 175.3%6 of 12 weeks ahead 100% evidence |
| Exact sum: 11 + 5.4 + 9 + 19.1 = 44.5 · Decision use: Price leads the evidence: RS versus the benchmark is 53.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22Monolithic Power Systems, Inc.MPWR | 42.8/100Mixed-negative evidence81% evidence | ASLEEP | 17.6/35 Revenue 28.6% · PAT -56.8% · OPM change 6.2 pp 83% evidence | 13.9/25 ROCE 7.8% · OPM 31% 76% evidence | 5.6/20 P/E 84.6× · PEG 3.59 65% evidence | 5.7/20 RS sector -25.6% · RS bench -9.9% · 1Y 25.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 13.9 + 5.6 + 5.7 = 42.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23STMicroelectronics N.V.STM | 40.0/100Mixed-negative evidence64% evidence | ASLEEP | 17.8/35 Revenue 10.5% · PAT -27% · OPM change 10.2 pp 62% evidence | 5.7/25 ROCE 0.8% · OPM 5.4% 76% evidence | 9.1/20 P/E 139.1× · PEG — 15% evidence | 7.4/20 RS sector -6.1% · RS bench 7.9% · 1Y 72.9%3 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 5.7 + 9.1 + 7.4 = 40 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Arm Holdings plcARM | 39.6/100Mixed-negative evidence81% evidence | ASLEEP | 14.7/35 Revenue 25.1% · PAT 49.4% · OPM change -3.2 pp 83% evidence | 10.4/25 ROCE 8.9% · OPM 7.6% 76% evidence | 3.7/20 P/E 362.7× · PEG 7.72 65% evidence | 10.8/20 RS sector 2% · RS bench 17.6% · 1Y 70.7%7 of 12 weeks ahead 100% evidence |
| Exact sum: 14.7 + 10.4 + 3.7 + 10.8 = 39.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Rambus Inc.RMBS | 38.7/100Thin evidence · provisional56% evidence | ASLEEP | 14.5/35 Revenue — · PAT — · OPM change -3.6 pp 39% evidence | 12.2/25 ROCE 5% · OPM 34.3% 76% evidence | 10.2/20 P/E 60.9× · PEG — 15% evidence | 1.8/20 RS sector -41.8% · RS bench -28% · 1Y -20.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 12.2 + 10.2 + 1.8 = 38.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26ON Semiconductor CorporationON | 37.8/100Thin evidence · provisional56% evidence | ASLEEP | 16.8/35 Revenue — · PAT — · OPM change 2.9 pp 39% evidence | 8.4/25 ROCE 2.2% · OPM 16.1% 76% evidence | 10.3/20 P/E 58.5× · PEG — 15% evidence | 2.3/20 RS sector -27.1% · RS bench -13.8% · 1Y 30.4%2 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 8.4 + 10.3 + 2.3 = 37.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27GLOBALFOUNDRIES Inc.GFS | 29.9/100Adverse evidence64% evidence | ASLEEP | 11.7/35 Revenue 1.4% · PAT — · OPM change -1.9 pp 62% evidence | 7.5/25 ROCE 1.2% · OPM 9.7% 76% evidence | 10.0/20 P/E 64.4× · PEG — 15% evidence | 0.7/20 RS sector -31.4% · RS bench -18.8% · 1Y 30.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 11.7 + 7.5 + 10 + 0.7 = 29.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Astera Labs, Inc.'s stock price today?
Astera Labs, Inc. trades at $269, +9.8% over the past year. The company is valued at $47.0 B. The stock sits at 51% of its 52-week range of $112–$417, +17.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 23 weeks in. — as of 17 September 2026.
What were Astera Labs, Inc.'s latest quarterly results?
Astera Labs, Inc. reported revenue of $0.4 B and net profit of $0.1 B for the Jun 26 quarter. Revenue rose 105.3% and profit rose 200.0% year on year. Earnings per share were $0.83. The operating margin was 23.1%, 2.0 pp higher than a year earlier. — as of 17 September 2026.
What is Astera Labs, Inc.'s revenue?
Astera Labs, Inc. reported revenue of $0.4 B in the Jun 26 quarter, +105.3% year on year. For the full FY25 fiscal year, revenue was $0.8 B (+112.5%). Over the last 3 years revenue compounded at 119.8% a year. — as of 17 September 2026.
What is Astera Labs, Inc.'s profit?
Astera Labs, Inc. earned $0.1 B of net profit in the Jun 26 quarter, +200.0% year on year — the 3rd straight quarter of growth. Full-year FY25 profit was $0.2 B. The operating margin ran 23.1% in the latest quarter. — as of 17 September 2026.
What is Astera Labs, Inc.'s market cap?
Astera Labs, Inc.'s market capitalisation is $47.0 B at a stock price of $269. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Astera Labs, Inc.'s P/E ratio?
Astera Labs, Inc. trades at a P/E of 132.6×, at the 17th percentile of its own 1-year range, against a long-run median of 159.2×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Astera Labs, Inc. pay a dividend?
No — Astera Labs, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
Is Astera Labs, Inc. overvalued?
On its own history, Astera Labs, Inc. looks cheap: its P/E of 132.6× has been cheaper only 17% of the time in 1 years (long-run median 159.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is Astera Labs, Inc. growing?
Yes — Astera Labs, Inc. is growing: latest-quarter revenue +105.3% year on year, profit +200.0%, and the margin +2.0 pp at 23.1%. The earnings engine currently reads: improving — as of 17 September 2026.
How is Astera Labs, Inc. performing?
Astera Labs, Inc. is in a confirmed uptrend, 23 weeks in. Its latest quarter's revenue rose 105.3% and profit rose 200.0% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
Is Astera Labs, Inc. in an uptrend?
Yes — the price is in a confirmed uptrend (week 23 of stage 2), trading +17.1% versus its 200-day average and at 51% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Astera Labs, Inc. beating the market?
Not lately — on a trailing-13-week view Astera Labs, Inc. is currently behind the S&P 500 (5 weeks and counting; last ahead the week of 2026-08-14), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 2.5 years the stock moved +285% against the S&P 500's +45% — ahead of the index over the full window. — as of 17 September 2026.
Will Astera Labs, Inc.'s stock price go up?
This page publishes no price forecast for Astera Labs, Inc. What it measures instead: the stock price is $269, the price is in a confirmed uptrend 23 weeks in. Its P/E of 132.6× sits at the 17th percentile of its own 1-year range. — as of 17 September 2026.
Is the market betting against Astera Labs, Inc.?
Somewhat — short interest is 5.8% of Astera Labs, Inc.'s tradable float, about 2.2 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Astera Labs, Inc. have too much debt?
No — Astera Labs, Inc.'s debt-to-equity is 0.03. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. The returns on this page are earned, not borrowed — as of 17 September 2026.
What is Astera Labs, Inc.'s capex?
Astera Labs, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 17 September 2026.
What is Astera Labs, Inc.'s cash flow?
Astera Labs, Inc. generated $0.3 B of operating cash flow in FY25 and $0.3 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.2 B, so operating cash ran ahead of profit. — as of 17 September 2026.
How financially safe is Astera Labs, Inc.?
On the balance sheet, the Z-score reads 93.20 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is Astera Labs, Inc. in its business cycle?
Astera Labs, Inc.'s FY25 operating margin was 20.0%, against a 4-year band of −75.0%–20.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 23.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Astera Labs, Inc. story?
Biggest watch item: the price is already 23 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Astera Labs, Inc. a stock worth studying right now?
This is not investment advice. The machine read: Astera Labs, Inc.'s multiple sits at its floor because earnings outran a hard multi-year rally — compression born of growth, not neglect. The quarters are still improving, and the P/E sits at the 17th percentile of its own 1-year range. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!